- Conditions
- Tonsillectomy Postoperative Adverse Events
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 2,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma, Glioblastoma, Glioblastoma Multiforme, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Midline Glioma, H3K27-altered
- Interventions
- Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2, Lorlatinib post Radiation
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2035
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Inadequate; Pulmonary Ventilation, Newborn, Infant, Very Low Birth Weight
- Interventions
- Nasal NIV-NAVA
- Device
- Lead sponsor
- Tarah T Colaizy
- Other
- Eligibility
- 7 Days to 1 Year
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa
- Conditions
- Central Line Bloodstream Infections
- Interventions
- Silver Alginate
- Device
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 1 Day to 3 Weeks
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- MomZing Exercise Videos Online, Standard Exercise DVD
- Interventions
- MomZing Web Program, Standard Exercise DVD
- Behavioral
- Lead sponsor
- University of Hawaii
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 499 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Honolulu, Hawaii
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Akron Children's Hospital
- Other
- Eligibility
- 13 Years to 19 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Akron, Ohio
- Conditions
- Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
- Interventions
- ANG003 Dose A, ANG003 Dose B, Creon
- Drug
- Lead sponsor
- Anagram Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 26
- States / cities
- Long Beach, California • Los Angeles, California • Denver, Colorado + 22 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 12
- States / cities
- Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more
- Conditions
- Bacterial Infections
- Interventions
- Ceftobiprole medocaril
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- Up to 3 Months
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 9
- States / cities
- Loma Linda, California • Los Angeles, California • South Bend, Indiana + 5 more
- Conditions
- Cystic Fibrosis
- Interventions
- Essential amino acid intake + Leucine vs total AA supplement
- Dietary Supplement
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Healthy Term Infants
- Interventions
- Milk based infant formula powder, Investigational Infant Formula #1, Investigational Infant Formula #2, Human Milk
- Other
- Lead sponsor
- Abbott Nutrition
- Industry
- Eligibility
- 1 Day to 11 Days
- Enrollment
- 399 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Mission Hills, California • Norwich, Connecticut + 17 more
- Conditions
- Down Syndrome
- Interventions
- Hip Helpers home program
- Other
- Lead sponsor
- University of St. Augustine for Health Sciences
- Other
- Eligibility
- 3 Months to 15 Months
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- San Marcos, California • Saint Augustine, Florida • Austin, Texas
- Conditions
- Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
- Interventions
- Lumacaftor Plus Ivacaftor Combination, Ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more
- Conditions
- Rare Diseases
- Interventions
- clinical whole genome sequencing (cWGS)
- Other
- Lead sponsor
- Illumina, Inc.
- Industry
- Eligibility
- 1 Day to 120 Days
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- Orange, California • St Louis, Missouri • Omaha, Nebraska + 2 more
- Conditions
- Reperfusion Injury, Post Cardiac Arrest Brain Injury
- Interventions
- LUTICIA - Light Utilization COX-Inhibitory Device)
- Device
- Lead sponsor
- Mitovation, Inc
- Industry
- Eligibility
- 48 Hours to 1 Year
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Not listed
- Enrollment
- 12,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2030
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 18 more
- Conditions
- Congenital Heart Disease (CHD)
- Interventions
- Breastfeeding clinical practice guideline (CPG) for congenital heart disease (CHD)
- Other
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Atlanta, Georgia + 5 more
- Conditions
- Congestive Heart Failure
- Interventions
- carvedilol, placebo
- Drug
- Lead sponsor
- Shaddy, Robert, M.D.
- Individual
- Eligibility
- 1 Day to 17 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more
- Conditions
- Dravet Syndrome
- Interventions
- fenfluramine
- Drug
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 1 Year to 23 Months
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- Memphis, Tennessee • Dallas, Texas • Seattle, Washington
- Conditions
- Cystic Fibrosis
- Interventions
- Hypertonic Saline, Isotonic Saline, Indium-DTPA, Technetium Sulfur Colloid
- Drug
- Lead sponsor
- Tim Corcoran
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- MLD, Krabbe Disease, ALD, MPS I, MPS II, MPS III, Vanishing White Matter Disease, GM3 Gangliosidosis, PKAN, Tay-Sachs Disease, NP Deficiency, Osteopetrosis, Alpha-Mannosidosis, Sandhoff Disease, Niemann-Pick Diseases, MPS IV, Gaucher Disease, GAN, GM1 Gangliosidoses, Morquio Disease, S-Adenosylhomocysteine Hydrolase Deficiency, Batten Disease, Pelizaeus-Merzbacher Disease, Leukodystrophy, Lysosomal Storage Diseases, Purine Nucleoside Phosphorylase Deficiency, Multiple Sulfatase Deficiency Disease
- Interventions
- Palliative Care, Hematopoetic Stem Cell Transplantation
- Other · Biological
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- Not listed
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2035
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Lysosomal Storage Disease, Peroxisomal Disorder
- Interventions
- Campath-1H, Clofarabine, Melphalan, Total Body Irradiation with Marrow Boosting, Hematopoietic stem cell transplantation, Cyclosporine A, Mycophenolate mofetil
- Drug · Radiation · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Fever, Adverse Event Following Immunisation
- Interventions
- Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 6 Weeks to 30 Weeks
- Enrollment
- 524 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Oakland, California • Atlanta, Georgia • New York, New York + 2 more
- Conditions
- HIV Infections
- Interventions
- CD4 Antigens
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 6
- States / cities
- San Francisco, California • Stanford, California • Chicago, Illinois + 2 more